Stock index futures rise as key inflation gauge looms

Stock index futures posted modest gains on Friday, with investors anticipating the release of the PCE price index, a key inflation gauge expected to show core PCE at +2.9% Y/Y. This follows Thursday's broad market decline, which was driven by stronger-than-expected U.S. economic data that tempered expectations for rapid Fed rate cuts and pushed Treasury yields higher. Separately, President Trump announced new 100% tariffs on branded pharmaceutical drugs, effective October 1, though an exemption for U.S. manufacturing may limit their broader impact.

Analysis

U.S. stock index futures are posting modest gains, with the S&P 500, Nasdaq 100, and Dow futures up between 0.2% and 0.3%, signaling a potential pause after a three-day market decline. The recent selloff was driven by stronger-than-expected economic data, including a downward revision in jobless claims and an upward revision to Q3 GDP, which prompted investors to scale back expectations for imminent and rapid Federal Reserve rate cuts. This sentiment shift is reflected in the bond market, where the 10-year Treasury yield rose 3 basis points to 4.18%. The market's immediate focus is on the forthcoming Personal Consumption Expenditures (PCE) price index, the Fed's preferred inflation metric. Consensus expectations point to a core PCE increase of 2.9% year-over-year, unchanged from the prior month, which will be a critical data point in shaping the monetary policy outlook. Separately, the announcement of a 100% tariff on branded pharmaceuticals, effective October 1, introduces sector-specific risk. However, analysis from UBS suggests the impact may be mitigated by an exemption for companies building or expanding manufacturing facilities in the U.S., a condition many established pharmaceutical firms may be able to meet with relative ease.

Key Decisions for Investors

• Investors should closely monitor the core PCE inflation data release, as a figure above the expected 2.9% Y/Y could intensify the recent market selloff by reinforcing the 'higher for longer' interest rate narrative.
• Holders of branded pharmaceutical stocks should assess their portfolio companies' U.S. manufacturing footprint, as firms heavily reliant on imports face significant tariff risk while those with existing or planned domestic facilities may be insulated.
• Given the market's heightened sensitivity to economic data and the recent volatility, it is prudent to exercise caution on initiating large new positions until the inflation data provides clearer direction on the Federal Reserve's policy path.